Overview of alternative oligonucleotide chemistries for exon skipping

Methods in Molecular Biology

Volumn 867, Issue , 2012, Pages 365-378

  Saleh, Amer F ^a   Arzumanov, Andrey A ^a   Gait, Michael J ^a  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

Antisense oligonucleotide; Backbone chemistry; Exon skipping; Therapy

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; PEPTIDE; PEPTIDE NUCLEIC ACID; RNA PRECURSOR;

ALTERNATIVE RNA SPLICING; ANIMAL; ARTICLE; CHEMISTRY; EXON; GENETICS; HUMAN;

ALTERNATIVE SPLICING; ANIMALS; EXONS; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; PEPTIDE NUCLEIC ACIDS; PEPTIDES; RNA PRECURSORS;

EID: 84859849888     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-767-5_23     Document Type: Article

References (78)

1. Debart F, Abes S, Deglane G, Moulton HM, Clair P, Gait MJ et al (2007) Chemical modifi-cation to improve the cellular uptake of oligonucleotides. Curr Top Med Chem 7:727-737 (Pubitemid 46681854)
2. Juliano RL (2005) Peptide-oligonucleotide conjugates for the delivery of antisense and siRNA. Curr Opin Mol Ther 7:132-138
3. Kurreck J (2003) Antisense technologies. Improvement through novel chemical modifi-cations. Eur J Biochem 270:1628-1644 (Pubitemid 36532522)
4. Kurreck J (2008) Therapeutic oligonucleotides. Royal Society of Chemistry, Cambridge
5. Zatsepin TS, Turner JJ, Oretskaya TS, Gait MJ (2005) Conjugates of oligonucleotides and analogues with cell penetrating peptides as gene silencing agents. Curr Pharm Des 11:3639-3654 (Pubitemid 41630990)
6. Bauman J, Jearawiriyapaisarn N, Kole R (2009) Therapeutic potential of splice-switching oligonucleotides. Oligonucleotides 19:1-14
7. Maier MA, Leeds JM, Balow G, Springer RH, Bharadwaj R, Manoharan M (2002) Nuclease resistance of oligonucleotides containing the tricyclic cytosine analogues phenoxazine and 9-(2-aminoethoxy)-phenoxazine ("G-clamp") and origins of their nuclease resistance properties. Biochemistry 41:1323-1327 (Pubitemid 34083786)
8. Holmes SC, Arzumanov A, Gait MJ (2003) Steric inhibition of human immunodeficiency virus type-1 Tat-dependent trans-activation in vitro and in cells by oligonucleotides containing 2 ¢-O-methyl G-clamp ribonucleoside analogues. Nucleic Acids Res 31:2759-2768 (Pubitemid 37442120)
9. Matsukura M, Shinozuka K, Zon G, Matsuya H, Reitz M, Cohen JS et al (1987) Phosphorothioate analogs of oligodeoxyribonucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci USA 84: 7706-7710
10. Straarup EM, Fisker N, Hedtjärn M, Lindholm MW, Rosenbohm C, Aarup V et al (2010) Short locked nucleic acid antisense oligonucleotides potently reduce apoliprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res 38:7100-7111
11. Eckstein F (2007) The versatility of oligonucleotides as potential therapeutics. Expert Opin Biol Ther 7:1021-1034 (Pubitemid 47208133)
12. Takeshima Y, Yagi M, Wada H, Ishibashi K, Nishiyama A, Kakumoto M et al (2006) Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy. Pediatr Res 59:690-694 (Pubitemid 43740012)
13. Takeshima Y, Yagi M, Wada H, Matsuo M (2005) Intraperitoneal administration of phosphorothioate antisense oligodeoxynucleotide against splicing enhancer sequence induced exon skipping in dystrophin mRNA expressed in mdx skeletal muscle. Brain Dev 27:488-493 (Pubitemid 41383489)
14. Kang S-H, Cho M-J, Kole R (1998) Up-regulation of luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development. Biochemistry 37:6235-6239 (Pubitemid 28213640)
15. Sierakowska H, Sambade MJ, Agrawal S, Kole R (1996) Repair of thalassemic human b-globin mRNA in mammalian cells by antisense oligonucleotides. Proc Natl Acad Sci USA 93: 12840-12844 (Pubitemid 26382730)
16. Dunckley MG, Manoharan M, Villiet P, Eperon IC, Dickson G (1998) Modification of splicing in the dystrophin gene in cultured mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet 7:1083-1090 (Pubitemid 28306871)
17. Lu QL, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter J et al (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 102:198-203 (Pubitemid 40094452)
18. van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M et al (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357:2677-2686
19. Goto M, Sawamura D, Nishie W, Sakai K, McMillan JR, Akiyama M et al (2006) Targeted skipping of a single exon harboring a premature termination codon mutation: implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients. J Invest Dermatol 126: 2614-2620 (Pubitemid 44764045)
20. Mulders SAM, van den Broeck WJAA, Wheeler T, Croes HJ, van Kuik-Romeijn P, de Kimpe SJ et al (2009) Triplet-repeat oligonucleotidemediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci USA 106:13915-13920
21. Karras JG, McKay RA, Dean NM, Monia BP (2000) Deletion of individual exons and induction of soluble murine interleukin-5 receptoralpha chain expression throygh antisense oligonucleotide-mediated redirection of premRNA splicing. Mol Pharmacol 58:380-387 (Pubitemid 30497482)
22. Vickers TA, Zhang H, Graham MJ, Lemonidis KM, Zhao C, Dean NM (2006) Modification of MyD88 mRNA splicing and inhibition of IL-1 signaling in cell culture and in mice with a 2 ¢-O-methoxyethyl-modified oligonucleotide. J Immunol 176:3652-3661 (Pubitemid 43364012)
23. Sazani P, Kang S-H, Maier MA, Wei C, Dillman J, Summerton J et al (2001) Nuclear antisense effects of neutral, anionic and cationic analogs. Nucleic Acids Res 29:3965-3974 (Pubitemid 32962686)
24. Hua Y, Sahashi K, Hung G, Rigo F, Passini MA, Bennett CF et al (2010) Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 24:1634-1644
25. Hua Y, Vickers TA, Baker BF, Bennett CF, Krainer AR (2007) Enhancement of SMN2 Exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol 5:e73
26. Sazani P, Gemignani F, Kang S-H, Maier MA, Manoharan M, Persmark M et al (2002) Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat Biotechnol 20:1228-1233 (Pubitemid 35462487)
27. Koshkin AA, Singh SK, Nielsen P, Rajwanshi VK, Kumar R, Meldgaard M et al (1998) LNA (Locked Nucleic Acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron 54: 3607-3630 (Pubitemid 28108183)
28. Obika S, Morio K-I, Hari Y, Imanishi T (1999) Preparation and properties of 2 ¢ ,5 ¢-linked oligonucleotide analogues containing 3 ¢-O,4 ¢-Cmethyleneribonucleosides. Biorg Med Chem Lett 9:515-518 (Pubitemid 29090642)
29. Takagi M, Yagi M, Ishibashi K, Takeshima Y, Surono A, Mastuo M et al (2004) Design of 2 ¢-O-Me RNA/ENA chimera oligonucleotides to induce exon skipping in dystrophin premRNA. Nucleic Acids Symp Ser 48:297-298
30. Aartsma-Rus A, Kaman WE, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen G-JB et al (2004) Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells. Gene Ther 11:1391-1398 (Pubitemid 39263892)
31. Elayadi AN, Braasch DA, Corey DR (2002) Implications of high-affinity hybridization by locked nucleic acid oligomers for inhibition of human telomerase. Biochemistry 41:9973-9981 (Pubitemid 34839743)
32. Arzumanov A, Walsh AP, Rajwanshi VK, Kumar R, Wengel J, Gait MJ (2001) Inhibition of HIV-1 Tat-dependent trans-activation by steric block chimeric 2 ¢-O-methyl/LNA oligoribonucleotides. Biochemistry 40:14645-14654 (Pubitemid 33111748)
33. Fabani M, Gait MJ (2008) miR-122 targeting with LNA/2 ¢-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNApeptide conjugates. RNA 14:336-346 (Pubitemid 351171593)
34. Roberts J, Palma E, Sazani P, Ørum H, Cho M, Kole R (2006) Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice. Mol Ther 14:471-475 (Pubitemid 44296096)
35. Graziewicz MA, Tarrant TK, Buckley B, Robert J, Fulton L, Hansen H et al (2008) An endogenous TNF-alpha antagonist induced by spliceswitching oligonucleotides reduces infl ammation in hepatitis and arthritis mouse models. Mol Ther 16:1316-1322 (Pubitemid 351866064)
36. Yagi M, Takeshima Y, Surono A, Takagi M, Koizumi M, Matsuo M (2004) Chimeric RNA and 2 ¢-O, 4 ¢-C-ethylene-bridged nucleic acids have stronger activity than phosphorothioate oligodeoxynucleotyides in induction of exon 19 skipping in dystrophin mRNA. Oligonucleotides 14:33-40 (Pubitemid 38524633)
37. Egholm M, Buchardt O, Nielsen PE, Berg RH (1992) Peptide nucleic acids (PNA). Oligonucleotide analogues with an achiral backbone. J Am Chem Soc 114:1895-1897
38. Egholm M, Buchardt O, Christensen L, Behrens C, Freier SM, Driver DA et al (1993) PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen bonding rules. Nature 365:566-568 (Pubitemid 23317782)
39. Karras JG, Maier MA, Lu T, Watt A, Manoharan M (2001) Peptide nucleic acids are potent modulators of endogenous pre-mRNA splicing of the murine interleukin-5 receptor-a chain. Biochemistry 40:7853-7859 (Pubitemid 32622976)
40. Siwkowski AM, Malik L, Esau CC, Maier MA, Wancewicz EV, Albertshofer K et al (2004) Identification and functional validation of PNAs that inhibit murine CD40 expression by redirection of splicing. Nucleic Acids Res 32:2695-2706 (Pubitemid 38885941)
41. Yin H, Lu Q, Wood M (2008) Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Mol Ther 16:38-45
42. Yin H, Betts C, Saleh AF, Ivanova GD, Lee H, Seow Y et al (2010) Opimization of peptide nucleic acids antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse. Mol Ther 18:819-827
43. Summerton J, Weller D (1997) Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 7:187-195 (Pubitemid 27323077)
44. Moulton HM, Moulton JD (2008) Antisense morpholino oligomers and their peptide conjugates. In: Kurreck J (ed) Therapeutic oligonucleotides. Royal Society of Chemistry, Cambridge, pp 43-79
45. Moulton HM, Moulton JD (2010) Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim Biophys Acta 1798:2296-2303
46. Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C et al (2009) Restoration of dystrophin expression in Duchenne muscular dystrophy: a single blind placebo-controlled dose escalation study using morpholino oligomer AVI-4658. Lancet Neurol 8:918-928
47. Schmajuk G, Sierakowska H, Kole R (1999) Antisense oligonucleotides with different backbones. Modification of splicing pathways and efficacy of uptake. J Biol Chem 274: 21783-21789
48. Gebski BL, Mann CJ, Fletcher S, Wilton SD (2003) Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum Mol Genet 12:1801-1811 (Pubitemid 36944135)
49. Alter J, Lou F, Rabinowitz A, Yin H, Rosenfield J, Wilton SD et al (2006) Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12:175-177 (Pubitemid 43214742)
50. Fletcher S, Honeyman K, Fall AM, Hardin PL, Johnsen RD, Wilton SD (2006) Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J Gene Med 8:207-216 (Pubitemid 43250701)
51. Heemskerk HA, de Winter CL, de Kimpe SJ, van Kuik-Romeijn P, Heuvelmans N, Platenburg G et al (2009) In vivo comparison of 2 ¢-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med 11:257-266
52. Wheeler TM, Sobczak K, Lueck JD, Osborne RJ, Lin X, Dirksen RT et al (2009) Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 325:336-339
53. Fattal E, Bochot E (2008) State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers. Int J Pharm 364:237-248
54. Zhao X, Pan F, Holt CM, Lewis AL, Lu JR (2009) Controlled delivery of antisense oligonucleotides: a brief review of current strategies. Expert Opin Drug Deliv 6:673-686
55. Ferlini A, Sabatelli P, Fabris M, Bassi E, Falzaranos S, Vattemi G et al (2010) Dystrophin restoration in skeletal, heart and skin arrector pili smooth muscle of mdx mice by ZM2 NP-AON complexes. Gene Ther 17:432-438
56. Williams JH, Schray RC, Sirsi S, Lutz GJ (2008) Nanopolymers improve delivery of exon skipping oligonucleotides and concomitant dystrophin expression on skeletal muscle of mdx mice. BMC Biotechnol 8:35
57. Lebleu B, Moulton HM, Abes R, Ivanova GD, Abes S, Stein DA et al (2008) Cell penetrating peptide conjugates of steric block oligonucleotides. Adv Drug Deliv Rev 60:517-529 (Pubitemid 351217082)
58. Said HF, Saleh AF, Abes R, Gait MJ, Lebleu B (2010) Cell penetrating peptides: overview and applications to the delivery of oligonucleotides. Cell Mol Life Sci 67:715-726
59. Abes S, Moulton HM, Clair P, Prevot P, Youngblood DS, Wu RP et al (2006) Vectorization of morpholino oligomers by the (R-Ahx-R) 4 peptide allows efficient splicing correction in the absence of endosomolytic agents. J Control Release 116:304-313 (Pubitemid 44827406)
60. Abes R, Arzumanov A, Moulton HM, Abes S, Ivanova GD, Iversen PL et al (2007) Cellpenetrating-peptide-based delivery of oligonucleotides: an overview. Biochem Soc Trans 35:775-779
61. Bendifallah N, Rasmussen FW, Zachar V, Ebbesen P, Nielsen PE, Koppelhus U (2006) Evaluation of cell-penetrating peptides (CPPs) as vehicles for intracellular delivery of antisense peptide nucleic acid (PNA). Bioconjug Chem 17:750-758 (Pubitemid 43794386)
62. El-Andaloussi S, Johansson HJ, Lundberg P, Langel U (2006) Induction of splice correction by cell-penetrating peptide nucleic acids. J Gene Med 8:1262-1273 (Pubitemid 44660525)
63. Abes R, Moulton HM, Clair P, Yang ST, Abes S, Melikov K et al (2008) Delivery of steric block morpholino oligomers by (R-X-R)4 peptides: structure-activity studies. Nucleic Acids Res 36:6343-6354
64. Abes S, Turner JJ, Ivanova GD, Owen D, Williams D, Arzumanov A et al (2007) Efficient splicing correction by PNA conjugation to an R 6-Penetratin delivery peptide. Nucleic Acids Res 35:4495-4502 (Pubitemid 47244600)
65. Ivanova GD, Arzumanov A, Abes R, Yin H, Wood MJ, Lebleu B et al (2008) Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res 36:6418-6428
66. Wancewicz EV, Maier MA, Siwkowski AM, Altertshofer K, Winger TM, Berdeja A et al (2010) Peptide nucleic acids conjugated to short basic peptide show improved pharmacokinetics and antisense activity in adipose tissue. J Med Chem 53:3919-3926
67. Jearawiriyapaisarn N, Moulton HM, Buckley B, Roberts J, Sazani P, Fucharoen S et al (2008) Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther 16: 1624-1629
68. Wu B, Moulton HM, Iversen PL, Jiang J, Li J, Li J et al (2008) Effective rescue of dystrophin improves cardiac function in dystrophin-defi-cient mice by a modifies morpholino oligomer. Proc Natl Acad Sci USA 105:14814-14819
69. Yin H, Moulton HM, Seow Y, Boyd C, Boutilier J, Iverson P et al (2008) Cellpenetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet 17:3909-3918 (Pubitemid 352762853)
70. Yin H, Moulton HM, Betts C, Seow Y, Boutilier J, Iversen PL et al (2009) A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet 18:4405-4414
71. Yin H, Saleh AF, Betts C, Camiletti P, Seow Y, Ashraf S, Arzumanov A, Gait MJ, Wood MJA (2011) Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol Ther 19:1295-1303.
72. Alam MR, Dixit V, Kang H, Li ZB, Chen X, Trejo J et al (2008) Intracellular delivery of an anionic antisense oligonucleotide via receptor mediated endocystosis. Nucleic Acids Res 36:2764-2776 (Pubitemid 351659588)
73. Ming X, Alam MR, Fisher M, Yan Y, Chen X, Juliano RL (2010) Intracellular delivery of an antisense oligonucleotide via endocytosis of a G-protein coupled receptor. Nucleic Acids Res 38:6567-6576
74. Wu B, Li Y-F, Morcos PA, Doran TJ, Lu P, Lu QL (2009) Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. Mol Ther 17:864-871
75. Davis S, Propp S, Freier SM, Jones LE, Serra MJ, Kinberger G et al (2009) Potent inhibition of microRNA in vivo without degradation. Nucleic Acids Res 37:70-77
76. Frieden M, Christensen SM, Mikkelsen N, Rosenbohm C, Thrue CA, Westergaard M et al (2003) Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA. Nucleic Acids Res 31:6365-6372 (Pubitemid 37442364)
77. Prakash TP, Siwkowski AM, Allerson CR, Migawa MT, Lee S, Gaus HJ et al (2010) Antisense oligonucleotides containing conformationally constrained 2 ¢ ,4 ¢-(N-methoxy) aminomethylene and 2 ¢ ,4 ¢- aminooxymethylene and 2 ¢-O,4 ¢-C-aminomethylene bridged nucleoside analogues show improved potency on animal models. J Med Chem 53:1636-1650
78. Seth PP, Siwkowski AM, Allerson CR, Vasques G, Lee S, Prakash TP et al (2009) Short antisense oligonucleotides with novel 2 ¢-4 ¢ conformationally restricted nucleoside analogues show improved potency without increased toxicity in animals. J Med Chem 52:10-13